TriSalus Life Sciences, Inc. (TLSI) Stock Forecast
TLSI analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $10.40 average of analyst targets
- Upside to target
- +186.5% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.14
- 52-week range
- $2.52 – $7.50
TLSI analyst ratings
5 analystsNumber of analysts at each rating.
TLSI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TLSI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.15 | −$0.09 | −$0.96 | +86.7% | 5 |
| Current fiscal year (2026) | −$0.33 | −$0.39 | −$0.27 | −$1.84 | +82.1% | 5 |
| Next fiscal year (2027) | −$0.26 | −$0.38 | $0.02 | −$0.33 | +20.0% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TLSI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $14.0M | $13.0M | $14.5M | +21.2% | 5 |
| Current fiscal year (2026) | $53.1M | $49.1M | $55.5M | +17.6% | 5 |
| Next fiscal year (2027) | $74.5M | $70.1M | $81.7M | +40.3% | 5 |
TLSI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TLSI revenue: reported and forecast
TLSI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.12 | −$0.12 | −$0.13 | +24.9% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.29 | −$0.29 | −$0.33 | −$0.33 | −$0.33 | +13.8% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.16 | −$0.14 | −$0.26 | −$0.26 | −$0.26 | +61.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TLSI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TLSI beat in 4 of 11.
What analysts expect from TLSI
5 analysts cover TriSalus Life Sciences; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.40, 186.5% above the latest close of $3.63. Analysts expect earnings of −$0.33 per share for 2026, +82.1% from a year earlier. For 2027 the average estimate is −$0.26 per share on revenue of $74.5 million. TriSalus Life Sciences beat the EPS estimate in 4 of the last 11 quarters.
Related: TLSI income statement, TLSI key metrics, TLSI chart. See the TLSI stock overview for the latest quote and news.
TLSI forecast FAQ
What is TriSalus Life Sciences's price target?
The average analyst price target for TriSalus Life Sciences is $10.40, 186.5% above the latest close of $3.63.
Is TriSalus Life Sciences a buy, hold or sell?
Of 5 analysts covering TriSalus Life Sciences, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is TriSalus Life Sciences's EPS forecast?
Analysts forecast −$0.33 per share for 2026 (range −$0.39 to −$0.27); for 2027 the estimate is −$0.26.
What is TriSalus Life Sciences's revenue forecast?
The average revenue estimate for 2026 is $53.1 million, growth of 17.6%; for 2027 it is $74.5 million.
When does TriSalus Life Sciences report earnings?
TriSalus Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.14.
Does TriSalus Life Sciences usually beat earnings estimates?
TriSalus Life Sciences reported EPS at or above the analyst estimate in 4 of the last 11 quarters.